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A transgenic Sprague Dawley rat bearing the A30P and A53T α-synuclein (α-syn) human mutations under the control of the
tyrosine hydroxylase promoter was generated in order to get a better understanding of the role of the human α-syn mutations on
the neuropathological events involved in the progression of the Parkinson’s disease (PD). This rat displayed olfactory deﬁcits in
the absence of motor impairments as observed in most early PD cases. In order to investigate the role of the mutated α-syn on cell
proliferation, we focused on the subventricular zone (SVZ) and the olfactory bulbs (OB) as a change of the proliferation could
aﬀect OB function. The eﬀect on OB dopaminergic innervation was investigated. The human α-syn co-localized in TH-positive
OB neurons. No human α-syn was visualized in the SVZ. A signiﬁcant increase in resident cell proliferation in the glomerular but
notinthegranularlayersoftheOBandintheSVZwasobserved.THinnervationwassigniﬁcantlyincreasedwithintheglomerular
layer without an increase in the size of the glomeruli. Our rat could be a good model to investigate the role of human mutated
α-syn on the development of olfactory deﬁcits.
1.Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder. It is mainly characterized
by a progressive and massive loss of dopaminergic (DA)
neurons in the substantia nigra pars compacta (SNpc),
which leads to several clinical motor symptoms such as
akinesia, rigidity and resting tremor [1, 2]. The molecular
pathways leading to these concomitant clinical alterations
remain obscure, but it is believed that it may result from
environmental factors, genetic causes, or a combination
of the two [3]. The ﬁrst gene discovered involved in the
disease was the α-synuclein (α-syn) gene. Mutations of this
gene are responsible for autosomal dominants forms of
PD [4, 5]. Indeed, three missense mutations in the α-syn
gene have been found in patient families: A30P, A53T, and
E46K [4, 6, 7]. Alpha-syn has an increased propensity to
aggregate due to its hydrophobic nonamyloid-β component
domain and the presence of ﬁbrillar α-syn as a major
structural component of Lewy body, a pathological hallmark
of Parkinson’s disease and suggests a role of aggregated α-syn
in disease pathogenesis [8]. Alpha-syn is a natively unfolded
presynaptic protein which has a role in compartmental-
ization, storage, and recycling of neurotransmitters. It is
involved in physiological regulation of certain enzymes such
as tyrosine hydroxylase (TH) and increases the number of
dopamine transporter molecules [1]. On the contrary, it is
implicated in downregulation of the activity of the vesicular
monoamine transporter-2 (VMAT-2).2 Parkinson’s Disease
In order to understand better the eﬀects of the α-syn
mutation on the neuropathology and progression of PD,
transgenic mouse models were generated. However, mostly
due to the choice of the promoter, the expression of mutated
human α-syn was often located in non-DA brain structures
[9–11]. In addition, when α-syn aggregates were visualized
in the SNpc, no signiﬁcant DA neuronal cell loss was noticed
although motor deﬁcits were observed [1, 11–15].
These transgenic mice models were more suitable to
study whole brain α-synucleinopathy than to investigate the
p r e c i s er o l eo fα-syn on DA structures, therefore a search
for better animal models of PD continued. Thus, about a
decade ago, Lo Bianco et al. [16] and Yamada et al. [17]
showedthatlentiviralvectorsexpressingwild-typeormutant
human A30P and A53T forms of α-syn injected into the rat
SNpc induced, in contrast to transgenic mouse models, a
s e l e c t i v el o s so fn i g r a lD An e u r o n s ,D Ad e n e r v a t i o no ft h e
striatumaswellassigniﬁcantmotorimpairments[18].These
studies demonstrated that the rat has speciﬁc sensitivity of
SNpc DA neurons to human α-syn, but this new model of
PD lacked the progressive nature of the disease observed in
humans.Inthelightofthesepreviousstudies,wegenerateda
transgenicratbearingboththeA30PandA53Tα-synhuman
mutations [19, 20] in order to get a better understanding
of the human α-syn role on the neuropathological events
involved in the progression of the disease. In the mouse, the
A30P mutant form [21] or the A53T mutant form [22]o fα-
syn showed a decrease in the neurogenesis in the glomerular
and granular layers of the olfactory bulbs (OBs). This is the
reason why the present study focused on the subventricular
zone (SVZ) proliferation and the OB local proliferation.
AlterationofSVZandlocalOBproliferationcouldalsoaﬀect
OB function, as most of the time, hyposmia precede clinical
motor symptoms in Parkinson’s disease [23].
In the adult brain, neural stem cells from the anterior
portionoftheSVZgiverisetoneuroblaststhatmigratealong
the rostral migratory stream to the OB [24]. Within the
granulecellandglomerularlayersoftheOB,apersistentpro-
liferative activity of progenitor cells is observed [24]. Then,
the cells diﬀerentiate into functional granular GABAergic
and periglomerular DA olfactory interneurons.
To summarize, we investigated the eﬀects of the human
double A30P and A53T α-syn mutations on SVZ and
local OB proliferation with an additional focus on OB DA
innervations [25].
2.MaterialsandMethods
2.1. Generation of the Transgenic Human A53T and A30P
α-synuclein Rat. The transgene construct pUTHTV hm2α-
SYN (Figure 1) was created by Richﬁeld et al. [14]a n d
kindly given by H.J Federoﬀ (University of Rochester, New
York). Brieﬂy, the transgene was composed of the A30P
and A53T double mutated form of human α-syn under the
control of the rat tyrosine hydroxylase (TH) promoter. The
current method of gene transfer, microinjection, which is
widely used in transgenic mouse production, was successful
in obtaining transgenic rats. The microinjection of Sprague
Dawley rat ovocytes into male pronucleus were generated
by the INSERM UMR643 transgenic rat common facility
(Nantes, France) and by genOway company (Lyon, France).
The present study was performed with one of the 3
transgenic rat lines that were generated, the MA3 transgenic
rat line.
All experiments were carried out in accordance with
the regulations of the University of Nantes Animal Health
Committee.
2.1.1. Analysis of the Olfaction, Modiﬁed from Lemasson et al.
[26] and Gross Motor Locomotion. After habituation, the
animal was placed one time per month in the middle of
an open ﬁeld apparatus (600 × 600 × 400mm) equipped
with infrared beams and connected to a computer to analyze
locomotion and time spent in the four quadrants of the
maze for a 2-minute period (Imetronic, Pessac, France). In
one corner, a ﬁlter paper (70 × 30mm) located at a height
of 10cm, was soaked in fresh coconut milk (half diluted in
distilled water; Tables du Monde, Leclerc Company France).
Coconut milk is known to be a very attractive odor for the
rat. In the opposite corner, the same size paper ﬁlter was
soaked in distilled water, considered as a neutral odor. The
time spent by the rat in both corners is recorded. The results
are expressed as the ratio of time spent in the corner with
the coconut milk ﬁlter paper/the time spent in the corner
with the distilled water ﬁlter paper. A higher ratio (i.e., more
time spent in the corner with the coconut milk ﬁlter paper)
demonstrates that the animal was able to smell the odor of
the coconut milk. During habituation and olfaction testing,
the animals were studied for locomotor impairments by a
hidden observer. Five animals were used in both groups. The
day before the ﬁrst olfaction testing, the rat is placed in the
apparatus (without ﬁlter paper) for 30min. During olfaction
testing, the rat is recorded to examine if there was any gross
impairments in the motor pattern.
2.1.2. Lateral Stepping Test and Movement Initiation. Each
animal was systematically handled on a regular basis for
several days before the ﬁrst assessment. Brieﬂy, in this test
evaluating the initiation of the movement, the experimenter
ﬁrmly suspended the rat’s hindquarters and restricted one
of its forelimbs, while the rat supported its weight on the
other forelimb. Then, the experimenter moved the rat along
the table (0.9m in 5seconds) on the right limb, three times
consecutively per session. Then, the rat undergoes the same
test for its left paw. All the sessions (left and right) were
recorded to allow the number of adjusting steps to be
counted by an investigator blinded to the state of the rat (i.e.,
transgenic or wild type). For each session (left and right),
the total score calculated was the mean of the number of
adjusting steps observed in the three tests (for the right and
the left paw). Then data from left and right were averaged
giving one value per animal. Data are presented as mean
values per group.
2.2. BrdU Injection. Groups of 5 wild-type (WT) and 4
transgenic female Sprague Dawley rats were sacriﬁced atParkinson’s Disease 3
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Figure 1: (a) Transgene construction. The transgene construct pUTHTV hm2α-Syn is composed of double mutated form of human α-syn
(hm2α-SYN) with A30P and A53T mutations under the control of the 9-kb rat tyrosine hydroxylase promoter. (b) There is a signiﬁcant
diﬀerence in the ratio odor/H20 between the 2 groups of rats (∗P<. 05, with the odor being from the coconut milk) in the olfaction test. The
WT rats spent more time in the corner with the coconut milk ﬁlter paper as compared to the corner with the distilled water (ratio superior
to 2). Transgenic animals spent less time in the corner with the coconut milk as a ratio of 1 corresponds to the same period of time spent in
bothcorners.Nosigniﬁcant ratiodiﬀerence was observed between 6, 9, and 14 months forboth groups of animals. (c)There is no signiﬁcant
diﬀerence in lateral stepping performance between WT and Tg animals indicating that no motor deﬁcits in 18-month old Tg animals.
25months of age. At that age, transgenic rats displayed a
severe olfactory deﬁcit. In order to label proliferative cells,
BrdU (100mg/Kg) was injected intraperitoneally once a day
during 5 consecutive days and the animals were sacriﬁced
5hours after the last injection. This protocol was aimed to
detectlocalproliferationratherthanneurogenesisaschanges
in local OB proliferation could take part in the olfactory
alterations observed in our transgenic rat.
2.3. Tissue Preparation. All animals were deeply anesthetized
with Rompun/Ketamine (1mL/Kg i.m.) and transcardially
perfused with ice-cold 4% paraformaldehyde in phosphate
buﬀered(PB).Brainswererapidlyremoved,immersedinthe
s a m eﬁ x a t i v ef o r2 4ha t4 ◦C and stored in 15% sucrose in
PB for 48hours and then in 30% sucrose for an additional
24hours. Brains were then frozen at −40◦Ci ni s o p e n -
tane (Prolabo, Fontenay-sous-Bois, France). Serial sixteen-
micrometer-thick coronal sections through the whole brain
were cut on a cryostat (Leica, CM 3050) and then collected
on gelatin-coated slides.
2.4. Immunohistochemistry. The brain sections were thor-
oughly washed with PBS prior to immunohistochemical
labeling. They were then labeled with antibodies against TH
to identify catecholaminergic neurons (1:1000; Pel-Freeze,
Brown Deer,WI), against the human-α-syn to characterized
neurons expressing the human α-syn (1:500; Invitrogen,
Cergy Pontoise, France) and against BrdU to quantify
proliferative cells (1:200; BD, USA). One section out of 6
serial sections was stained for each immunohistochemistry
labeling.4 Parkinson’s Disease
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Figure 2: Alpha-synuclein, tyrosine hydroxylase (TH), thioﬂavin T, and BrdU stainings in wild-type (WT) and transgenic (Tg) rats.
OverviewofTHexpressioninwild-type(WT,a)andtransgenic(Tg)olfactorybulbs(c).Alpha-synimmunostainingonasectionofolfactory
bulb of WT (b) and transgenic rat (d). Higher magniﬁcation of a Tg glomerular layer stained for TH in green (e), for α-syn in red (f), and
with merged stainings (g). Arrows point out some of the many neurons expressing both TH and α- s y n( s t a i n e di ny e l l o wi ng ) .C o n f o c a l
visualizations in transgenic rat of TH (h), human α-syn (i), and merged TH and α-syn (j). Arrows in h, i, and j point out a TH positive
neuron (in green) expressing the human α-syn (in red). (k) Visualization of protein aggregates (arrows) in a Tg glomerular layer using
thioﬂavin T, cell bodies are in red.Parkinson’s Disease 5
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Figure 3: Alpha-synuclein, tyrosine hydroxylase (TH), and BrdU immunoreactivity in wild-type (WT) and transgenic (Tg) rats. TH and
α-syn immunostainings in SVZ in a WT rat (a, b) and in a transgenic rat (c, d). BrdU immunostaining in SVZ in a WT rat (e, f) and in a
transgenic rat (g, h). No diﬀerence in the number of BrdU positive cells is observed between both groups. F and H are a higher magniﬁcation
of E and G, respectively. LV: lateral ventricle; Str: striatum. BrdU immunostaining in glomerular layer (I: WT; K: Tg) and granular cell layer
(J: WT; L: Tg) of a section of an olfactory bulb. We can observe an increase of the number of BrdU positive cells in the glomerular layer of
transgenic rats as compared to WT animals.
Brieﬂy, after treatment with H2O2 3% in PBS, sections
wereincubatedovernightinadilutionofprimaryantibodies.
Then, sections were immersed in a 1:500 dilution of
secondary biotinylated antibody (Jackson ImmunoResearch
Laboratories, West Grove, PA). Then sections were trans-
ferred to a Vectastain ABC Kit/PBS for 1hour (Vector Lab-
oratories, Burkingame, CA); 3,3 diaminobenzidine served as
chromogen in the subsequent visualization reaction.
For double immunochemistry labeling and confocal
visualization of TH and human α-syn, immunoﬂuorescent
secondary antibodies were used (anti-mouse IgG alexa568;
Invitrogen,CergyPontoise,Franceandanti-rabbitIgGFITC;
JacksonimmunoResearch Laboratories, West Grove, PA).
ForBrdUimmunohistochemistry,weusedaDNAdenat-
uration method consisting in ﬁrst 30min incubation at 37◦C
with 2N HCl in PBS followed by a second incubation in
0.1M Borax, pH: 8.6 for 30min.
Thioﬂavin T (Sigma, St Louis, USA) was used to detect
amyloid structure in proteins. Thioﬂavin T is a reagent
known to become strongly ﬂuorescent upon binding to
amyloid ﬁbrils. After 3 washes in PBS, brain sections were
immersed in a 1:500 dilution of TO-PRO-3 (Invitrogen,6 Parkinson’s Disease
Cergy Pontoise, France) to label the cell body in red. Then
sections were incubated for 1hour with thioﬂavin T (0.04%)
in a glycine solution (50mM).
2.5. Quantiﬁcation Procedure
2.5.1. Proliferative Cells. For BrdU quantiﬁcation of positive
cells within the SVZ, a rectangle (2500 × 1000mm) was
drawn around the structure and all stained cells (with a
clearly visible positive nucleus) were counted on each section
for a total of 10 equally spaced sections from bregma levels
1.70 to −0.40mm. The mean of these 10 values (one value
per section) was calculated giving one ﬁnal value per animal.
To get an unbiased estimate of the density of BrdU
positive cells within the OB granular and glomerular layers,
we used the dissector principle and random systematic
sampling [27]. The Mercator stereology analysis software
(Explora Nova, La Rochelle, France) was utilized to perform
unbiased stereological counts of BrdU positive cell. For
the unbiased quantiﬁcation, a line was drawn around the
granular or glomerular layers of each section (12 sections
from the 12 diﬀerent rostrocaudal levels in right and left
side of the brain were used). The observer was blinded to
the rat group. Cells were counted with a 40X objective (NA,
0.85) using a Nikon Eclipse E600 microscope (Tokyo, Japan)
withamotorizedstage(x, y,andz).Randomandsystematic
counting frames (50 × 50μm squares, regularly spaced by
200 μm) were used [28]. Only BrdU positive cells within the
frame were counted on sections (16-um serial sections, one
every six sections). A BrdU positive neuron was deﬁned as a
clearly visible BrdU-immunoreactive nucleus.
ThetotalnumberofBrdUpositiveneuronsinbothlayers
was also calculated using the formula Nt = Vt/Vu × Nu,
where Nt is the total number of BrdU positive neurons in
the layer, Vt is the total volume of the layer, Vu is the unit
volume in which the number of neurons was counted, and
Nu is the number of neurons counted in the unit volume.
Theaverageofthetotalamountofcellsforeachgroupwithin
the granular and the glomerular layers was then statistically
analyzed.
The global volume of the glomerular layer and granular
cell layer was estimated without bias (i.e., without systematic
error) from the proﬁle areas of the cut sections of the
glomerular and granular cell layers. An unbiased estimate
of each layer’s volume was done using Cavalieri’s principle.
Accordingly, we multiply the sum of the proﬁle areas
of each layer on all sections (regularly spaced) with the
distance between the sections [29]. With Vt = sum of
proﬁle areas × spacing between sections, spacing between
sections= 16μm (sections thickness) × 6 (one every six
s e c t i o n s ) .T h ea v e r a g eo ft h et o t a lv o l u m ef o ra l la n i m a l sw a s
then calculated.
2.5.2. TH Immunoreactivity in the OB. A measure of the
width of TH immunoreactivity within the glomerular layer
in the OB was performed. First, the OB was divided in 3
equal parts, from the anterior to the posterior axis (giving
3 values: one anterior (at bregma 6.7mm), one medial (at
Ventral level Median level
Dorsal level
Figure 4: Representation of the 3 dorso-ventral levels used to
quantify the width of TH innervation in the olfactory bulb
glomerular layer in wild-type and transgenic rats.
bregma 6.2mm), and one posterior (at bregma 5.7mm)),
each part containing 4 TH-stained sections spaced by 16
microns (for a total of 12 sections for the entire OB). Then,
for each animal, these 12 coronal sections were visualized
using the X4 magniﬁcation of an optical microscope (Nikon
Eclipse E600, Tokyo, Japan). The width of TH staining
corresponding to TH innervation was measured at 3 dorso-
ventral levels per section (dorsal, median, and ventral levels;
see Figure 4) in both left and right OB using the ImageJ
software(NationalInstitutesofHealth,Bethesda,MD).Then
the left and right measures from these 3 dorsoventral levels
obtained for each section were added together and the mean
of the 4 values from each 3 anterior-posterior OB levels was
calculated giving one ﬁnal value per animal for the anterior
part of the OB, one ﬁnal value per animal for the medial part
of the OB and one ﬁnal value per animal for the posterior
part of the OB.
2.5.3. Area of the Glomeruli. A measure of the area of the
glomeruliintheOBwasperformedon12THstainedcoronal
sections (from bregma 6.7mm to 5.7mm) in 3 transgenic
and 3 wild-type animals using the ImageJ software (National
Institutes of Health, Bethesda, MD). This quantiﬁcation was
performed in order to investigate if a variation in glomeruli
area could interact with a diﬀerence in glomerular layer
TH innervation pattern between the 2 groups of animals.
A total of 45 to 50 areas of glomeruli were measured per
animal. Seven area intervals were arbitrary used to rank
the glomeruli per size: 0–4330μm2; 4331–8660μm2; 8661–
12990μm2; 12991–17320μm2; 17321–21650μm2; 21651–
25980μm2; 25981–30310μm2. Data are represented as the
percentage of glomeruli for each area interval for each
animal.
2.6.StatisticalAnalysisoftheData. Resultsfromthebehavior
were expressed as mean± SEM and analyzed using an
ANOVA and Mann-Whitney. Data from BrdU labeling in
the SVZ and in the OB, glomerular TH innervation in the
OB and glomeruli area were expressed as mean ± SEM.
The density and total number of BrdU-positive cells and
the width of glomerular TH innervation were then analyzed
using the Mann-Whitney statistical test (one-tailed; PRISM;
Graph Pad 4.0 software, CA, USA).Parkinson’s Disease 7
3. Results
3.1. Generation of the A30P and A53T α-syn Transgenic Rat.
Using the transgene construction from Richﬁeld et al. ([14],
see Figure 1), 3 lines of transgenic rats expressing both the
A30P and A53T mutated forms of the human α-syn gene
under the control of the TH promoter have been generated.
However,only2founderswereabletotransmitthetransgene
to several generations of oﬀsprings as characterized by PCR
(not shown). The MA3 line characterized by 1 or 2 transgene
copies was used in our present investigation.
3.2. Investigation of the Olfaction. In the open ﬁeld, the
habituation pattern was identical for both groups of rats
(no corner preference). During the olfaction test, WT rats
were attracted by the odor of the coconut milk and spent
signiﬁcantly more time in the corner with the coconut milk
ﬁlter paper as compared to the corner with the distilled
water. A ratio of 2 indicates that the rat spent twice as much
time visiting the corner with the coconut milk as compared
to the corner with the distilled water. On the contrary,
transgenic animals signiﬁcantly spent less time in the corner
with the coconut milk as a ratio of 1 corresponds to the same
period of time spent in both corners. Therefore, transgenic
animals presented olfactory impairments when compared to
WT animals (Figure 1(b)). This impairment remained stable
from 6 months of age.
No gross alteration in locomotion pattern was observed
during the habituation and the olfaction test between both
groups of animals.
3.3. Lateral Stepping Test. No signiﬁcant diﬀerence in move-
ment initiation was observed between WT and Tg rats
from 14 to 18 months (Figure 1(c)). Results from gross
locomotor observations during the investigation of olfaction
were conﬁrmed in older rats with the lateral stepping test.
3.4. Immunohistochemistry. Distribution of human α-syn
protein and DA-labeled cells/processes in the OB and the
SVZ was evaluated by immunohistochemical investigation.
All transgenic MA3 brains expressed human α-syn protein
labeling in the OB (Figure 2(d)). Tyrosine hydroxylase and
human α-syn immunostainings were only detected in the
OB glomerular layer (Figures 2(a), 2(b), 2(c) and 2(d)) of
transgenic rats (the same location where the TH staining was
observed in WT animals, Figure 2(a)). Higher magniﬁcation
usingmergedﬂuorescenceofTHandα-synstainingsshowed
than most of TH positive neurons in the OB glomerular
layer also expressed the human α-syn (Figures 2(e), 2(f), and
2(d)). The confocal analysis conﬁrmed than both human
α-syn and TH molecules were colocalized in the same cell
bodies and processes with a diﬀuse cellular α-syn staining
pattern. The cell body contained dense patches positive for
human α-syn staining and a prominent immunoreactivity
in the processes (Figures 2(h), 2(i) and 2(g)). In addition,
using the Thioﬂavin T staining, numerous aggregates of
protein were noticed within the cell body (Figure 2(k)). The
antibody used to detect the human α-syn was validated by
the absence of any human α-syn staining in the OB of WT
rats (Figure 2(b)). Neither human α-syn positive cells nor
TH-labeled cells were visualized within the SVZ from WT
or transgenic animals (Figures 3(a), 3(b), 3(c), 3(d)).
BrdU-positive nuclei were observed in the SVZ area in
both WT and transgenic rats (Figures 3(e), 3(f), 3(g), and
3(h)). Proliferative-BrdU-labeled cells were also noticed in
the OB glomerular (Figures 3(i), 3(k)) and granular cell
layers (Figures 3(j), 3(l)). Fewer cells were noted in the WT
glomerular layer than in the Tg glomerular layer.
3.5. Quantiﬁcation of SVZ Proliferation. We performed
counts of BrdU immunoreactive cell bodies to measure the
level of SVZ proliferation. No signiﬁcant diﬀerence in BrdU
positive cells within the SVZ was noted between the 2 groups
of rats (Figures 3(e), 3(f), 3(g), 3(h), and Table 1).
3.6. Quantiﬁcation of OB New Generated Cells Within
Glomerular and the Granular Cell Layers. Following BrdU
injections, proliferation in the OB was assessed using unbi-
asedstereology.WhencomparingWTandtransgenicrats,no
signiﬁcant diﬀerence was observed in the density of resident
proliferated cells in the granular cell layer (mean density of
BrdU positive cells in transgenic group: 6.32 × 103 versus
5.78 × 103 intheWTgroup:(Figures3(j),3(l),andTable1).
In contrast, we observed a statistically signiﬁcant increase in
the density of BrdU positive cells in the glomerular layer of
transgenic rats as compared to WT animals (+68%; P<
.05; Figures 3(i) and 3(k) and Table 1). The analysis of
the total number of local proliferative cells also showed
a signiﬁcant increase only in the glomerular layer of the
transgenic animals as compared to the WT rats (Table 1).
No signiﬁcant variation in the volume of the glomerular
and granular layers was observed between the 2 groups of
animals (Table 1).
3.7. Quantiﬁcation of DA Innervation in Glomerular Layer.
To analyze DA innervations in the OB (Figure 4), the width
oftheTHpositiveareawithintheglomerularlayerevidenced
by TH immunolabeling was measured at 3 diﬀerent bregma
levels per section (anterior (6.7mm), medial (6.2mm) and
posterior (5.7mm)). An overall 7.9% increase in the width
of TH innervation was observed in the transgenic rat as
compared to WT animals. However, when the OBs were
divided along the anterior-posterior axis, only the width
calculatedat Bregma 6.2mm level wassigniﬁcantly increased
by 12.4% in transgenic rat as compared to WT rats (P<. 01;
Table 2).
3.8. Area of the Glomeruli. Glomeruli were distributed from
areas inferior to 4330μm2 to a maximum area of 30310μm2
with most of them having an area comprised between
8660μm2 and 12990μm2. No signiﬁcant diﬀerence was
observedconcerningthepercentageofglomeruliineacharea
interval, except for the smaller interval where signiﬁcantly
more transgenic glomeruli (3.47%) were contained in the “0
to 4330μm2” area interval as compared to 1.40% for the WT
glomeruli (P<. 05; Table 3).8 Parkinson’s Disease
Table 1: Quantiﬁcation of BrdU positive cells and layer’s volume in wild-type and transgenic rats from the olfactory bulb glomerular and
granular cell layers and in the SVZ. Mean ± SEM. ∗P<. 05; ns: no statistical diﬀerence between the 2 groups. Only the number of BrdU
positive cells in the glomerular layer of transgenic rats was signiﬁcantly increased by 68% as compared to WT animals. Values are expressed
as density per mm3and total number of BrdU positive neurons.
Wild-type group Transgenic group P<. 05
Glomerular layer density in mm3 1.72 ×103 ±0.38 ×103 2.90 ×103 ±0.51 ×103 ∗
Glomerular layer total number 2.35 ×103 ±0.52 ×103 4.13 ×103 ±0.72 ×103 ∗
Granular cell layer density in mm3 5.78 ×103 ±0.79 ×103 6.32 ×103 ±1.14 ×103 ns
Granular cell layer total number 16.6 ×103 ±2.28 ×103 19.27 ×103 ±3.48 ×103 ns
Subventricular zone total number 85.1 ×103 ±21.4 ×103 121 ×103 ±16.1 ×103 ns
Glomerular layer volume in mm3 1.364 ±0.21 1.423 ±0.06 ns
Granular layer volume in mm3 2.872 ±0.41 3.050 ±0.202 ns
Table 2: Measure of the width of TH innervation in the olfactory bulb glomerular layer in wild-type and transgenic rats. The width was
measured in the anterior level (bregma 6.7 mm), in the median level (bregma 6.2mm), and in the posterior level (bregma 5.7mm) of the
olfactory bulb. Mean ± SEM. ∗∗P<. 01; ns: no statistical diﬀerence between the 2 groups. A signiﬁcant increase of the TH innervation was
observed for bregma 6.2mm level in transgenic as compared to wild type rats.
Wild-type group Transgenic group P<. 01
Bregma: 6.7mm 434.2 ±16.46 480.9 ±34.23 ns
Bregma: 6.2mm 572.5 ±17.63 643.6 ±8.18 ∗∗
Bregma: 5.7mm 684.4 ±51.34 701.0 ±48.79 ns
4. Discussion
Our study used the ﬁrst α-syn transgenic rat bearing the
human A30P and A53T mutations under the control of
the TH promoter. As previously stated [19, 20] transgenic
animals displayed some long-lasting olfactory deﬁcits and
the human-mutated α-syn protein was observed in the
OB, the SNpc, and the LC. It was colocalized with TH
immunostaining (as shown for the OB in the present paper)
which is consistent with the fact that TH was the transgene
promoter. Olfactory deﬁcits appeared long before the motor
alterations as 18-month old animal did not present yet any
deﬁcit in movement initiation. Deﬁcits in motor coordina-
tion appeared at 19 months of age (not shown). Twenty-ﬁve-
month-old transgenic rats were used in this study as clinical
and pathological manifestations of the α-syn mutations
appear in advanced age in PD, generally [22]. Tyrosine
hydroxylase was used as the promoter in order to obtain the
human α-syn synthesis only in catecholaminergic structures.
Indeed, we were able to observe transgene expression in the
3 main catecholaminergic brain areas involved in the course
of PD: the OB, the SNpc, and the locus coeruleus. To date,
there is a growing evidence of a prion-like transmission of α-
syn contained in aggregates from donor cell to recipient cell
[30].However,itdidnotseemtobethecaseinourtransgenic
rat as non-TH positive brain structures did not contain any
human α-syn molecule. However, we cannot rule out that
this mechanism did not happen within catecholaminergic
structures, thus potentiating the eﬀect of the transgene.
The OB is a brain region of particular interest because
Lewy neurites and bodies are present in this area in the
very early stages of the PD [31]. These inclusions consist
of aggregated form of α-syn with other components such as
phosphorylated neuroﬁlaments and ubiquitin [31]. As in PD
patients, we have shown that our mutant human A53T and
A30Pα-synexpressingratpresentedproteinaggregatesinthe
glomerular layer suggesting an implication of the human-
mutated α-syn in the cellular processing of aggregates, which
could in turn alter local OB proliferation.
Our data showed an increased number of proliferative
cells in the glomerular layer but not in the granular cell layer.
It is worth mentioning here that the BrdU protocol used in
the present study rather revealed local OB proliferation than
migrated cells from the SVZ to the OB as the animals were
given BrdU for 5days and sacriﬁced 5hours after the last
injection.
Interestingly, Winner et al. [32] showed in 2-month-old
female Wistar rats that the local dividing cells represented
less than 5% of the total number of new cells. Their total
number of BrdU positive cells in the granular (8,200 cells)
and glomerular layer (250) are lower than ours (16,600 cells
and 2,350 cells, resp.). This important diﬀerence in numbers
can be related to the concentration of BrdU used in Winner’s
studybeinghalfoftheoneweused,tothetimeofthesacriﬁce
after the last injection (2h versus 5h in our study), to the age
of the animal (2months versus 25months) and could point
out for a few cells an increase in granular and glomerular
layer local proliferation due to aging.
No variation in the SVZ proliferation was induced by the
double α-syn mutation. This later result can be explained by
the absence of any transgene expression within the SVZ. Our
observation in the SVZ is in agreement with the ﬁndings of
Maxreiter et al. [21] using a mouse expressing the human
A30Pmutantformoftheα-syn,whodidnotﬁndanychange
inSVZproliferation.UsingmiceexpressingtheA30Pmutant
form of α-syn under the control of the calcium/calmodulin-
dependent protein kinase II alpha (CaMK) promoter [21]Parkinson’s Disease 9
Table 3: Distribution of glomeruli (in %) by area from TH-stained sections in wild-type and transgenic groups. Seven intervals of area were
used: 0–4330μm2; 4330–8660μm2; 8660–12990μm2; 12990–17320μm2; 17320–21650μm2; 21650–25980 μm2; 25980–30310 μm2. Mean ±
SEM. ∗P<. 05; ns: no statistical diﬀerence between the 2 groups. There is no signiﬁcant diﬀerence between both groups except for the
smaller interval.
Interval Wild-type group Transgenic group P<. 05
0–4330μm2 1.403 ±0.701 3.471 ±0.486 ∗
4331–8660μm2 17.06 ±3.556 19.11 ±1.780 ns
8661–12990μm2 37.67 ±3.353 31.26 ±0.077 ns
12991–17320μm2 31.72 ±4.339 22.56 ± 3.162 ns
17321–21650μm2 7.423 ±2.246 17.63 ±3.261 ns
21651–25980μm2 3.405 ±0.642 3.217 ±1.725 ns
25981–30310μm2 1.307 ±1.307 2.731 ±0.254 ns
or expressing the A53T mutant form of α-syn under the
controlofthePDGF-promoter[22],twogroupsstudyingOB
neurogenesisfoundadecreaseinnewlygeneratedneuronsin
the glomerular and granular layers. Taken together, the data
on OB neurogenesis and from our own investigation suggest
thathumanα-synA30P/A53Tmutationsimpactsnewlygen-
erated neuroblasts during OB integration/diﬀerentiation as
wellaslocalOBproliferation.Incontrasttoourobservations
and certainly due to the promoter they used, Winner et al.
[22] and Maxreiter et al. [21] also observed some transgene
expression in noncatecholaminergic structures. Some data
suggest that the mutated α-syn could spread using a prion-
like transmission from cell to cell [30]. As a result, it is
possible that a more “α-syn toxic brain environment” was
created in the A30P and the A53T transgenic mouse brains
than in our rat brain. The increased local proliferation that
we noticed in the glomerular layer is in agreement with
data from the glomerular layer of PD patients [23]. This
later ﬁnding suggests that our rat model is a suitable tool
concerning the eﬀects of the α-syn mutations in the OB.
As proliferative cells within the glomerular layer are
known to diﬀerentiate in DA neurons [24], we investigated
theTHinnervationwithintheglomerularlayer.Weobserved
anincreaseinwidthoftheTHpositiveareaintheglomerular
layer without an increase in the size of the glomeruli (except
for the smaller interval in transgenic animals) suggesting
that this increased TH innervation was not induced by an
increased glomerular layer areas (as an increased glomeruli
size would have increased the size of the glomerular layer
which in turn could have enlarged the pattern of TH
innervation).Thisresultisagreementwiththe100%increase
in DA cell number in the glomerular layer from PD patients
[23]. Although the mechanisms underlying the enhanced
DA innervation in the OB glomerular layer remains to be
determined, various growth factors which play an important
role in OB proliferation and DA diﬀerentiation could be
involvedsuchasBDNF,GDNFandCNTF[33].Interestingly,
this increase in DA innervation observed in our transgenic
rat and in PD patients could explain, at least in part, the
olfactory deﬁcit observed both in our rat and in patients
as DA in the OB has an inhibitory action. Hyposmia can
be detected in PD patients in early stage of disease. Our
transgenic rats have been tested for olfactory function at
diﬀerent ages (from one week to 25months of age) and at
6 months of age they presented an alteration of olfaction.
Dopamine has an important role in mediating olfactory
information into the brain [34]. TH innervation is found
exclusively in glomerular layer of the OB [25]. In our rat,
the increase in TH innervation in this area might suggest an
increase in DA release. DA is known to induce an inhibition
between olfactory receptor cells and mitral cells within
glomerular layer [23]. D2 receptors are the most abundant
subtype of DA receptors in the glomerular layer [35]a n d
are involved in the decrease in synaptic transmission [34].
The increase of DA neurons caused by the A30P and the
A53T mutant forms of α-syn could induce a depression
in synaptic transmission and therefore compromises the
threshold for olfaction. This circuit is the ﬁrst step in the
process of ﬁnal consciousness of smell and therefore is
essential for the proper function of olfactory circuits. Data
from biopsies of patients diagnosed with PD support the
idea that olfactory impairment in PD do not result from
damage to the olfactory epithelium but is the consequence
of central-nervous alterations [36]. Thus our rat could be a
good model to investigate the role of human mutated α-syn
in the development of olfactory deﬁcits.
In conclusion, we generated a human double mutated α-
syn (A30P and A53T) transgenic rat presenting an alteration
of the local proliferation in the glomerular layer but neither
in the granular cell layer of the OB nor in the SVZ. In
addition, an increase in DA glomerular layer innervation was
noticed,whichmightberelatedtotheincreasedproliferation
observed in this layer. Further investigation should examine
the time course of the changes in the olfactory function
in regards to alterations in OB local proliferation as well
as elucidate the role of the increased DA function in the
olfactory deﬁcits we observed in our transgenic rat.
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